<div id="readability-page-1"><p>Burney Co. acquired a new position in shares of  Qiagen N.V. (NYSE:QGEN - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 38,699 shares of the company's stock, valued at approximately $1,729,000.</p><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>Other large investors also recently modified their holdings of the company. MAI Capital Management boosted its holdings in shares of  Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company's stock worth $47,000 after buying an additional 889 shares during the period.  Farther Finance Advisors LLC lifted its position in  Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after acquiring an additional 849 shares during the last quarter.  Allworth Financial LP lifted its position in  Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company's stock worth $53,000 after acquiring an additional 796 shares during the last quarter.  GAMMA Investing LLC boosted its holdings in shares of  Qiagen by 375.5% during the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company's stock worth $55,000 after acquiring an additional 980 shares during the period.  Finally, Cullen Frost Bankers Inc. grew its position in shares of  Qiagen by 13,144.4% in the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company's stock valued at $57,000 after purchasing an additional 1,183 shares during the last quarter. 70.00% of the stock is owned by institutional investors. </p><h2>Qiagen Stock Performance</h2><p>NYSE:QGEN opened at $45.30 on Monday. The stock has a fifty day moving average price of $46.10 and a 200-day moving average price of $47.11. The company has a market cap of $10.07 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 2.32 and a beta of 0.67. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. </p><p>Qiagen's stock is scheduled to reverse split on the morning of Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.</p><p>Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.57 EPS.  As a group, equities analysts anticipate that  Qiagen N.V. will post 2.26 EPS for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several analysts recently weighed in on the company. Wall Street Zen raised Qiagen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Sunday, December 21st. Citigroup cut Qiagen from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lowered their price objective for the stock from $55.00 to $50.00 in a research report on Thursday, December 11th. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Qiagen in a research report on Monday, December 22nd. Finally, Barclays  restated an &#34;overweight&#34; rating and issued a $55.00 price target (up from $53.00) on shares of Qiagen in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and an average price target of $49.61.</p><p><b>Read Our Latest Stock Report on QGEN</b></p><h2>Qiagen Company Profile</h2> (Free Report)<p>Qiagen NV <span>NYSE: QGEN<span></span></span> is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.  </p><p>The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Qiagen</li><li>Do not delete, read immediately</li><li>How the Rich Retire</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>How Long Will $1M Last in Retirement?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding QGEN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVFHRU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVFHRU4"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Qiagen Right Now?</h2><p>Before you consider Qiagen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.</p><p>While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

QGEN

<p>Burney Co. has acquired 38,699 shares of Qiagen N.V. (NYSE:QGEN) valued at approximately $1.73 million in Q3, as disclosed to the SEC. Other investors, including MAI Capital Management and Farther Finance Advisors, have also significantly increased their holdings in Qiagen. The stock is currently trading at $45.30, with a market cap of $10.07 billion. Qiagen recently reported earnings of $0.61 EPS, surpassing estimates. Analysts have mixed ratings on the stock, with an average target price of $49.61.</p>

Burney Co. Purchases Shares of 38,699 Qiagen N.V. $QGEN